Dunkle Lisa M, Izikson Ruvim
a Clinical Research , Protein Sciences Corporation , Meriden , CT , USA.
Expert Rev Vaccines. 2016 Aug;15(8):957-66. doi: 10.1080/14760584.2016.1203261. Epub 2016 Jul 4.
Influenza causes annual epidemics worldwide that pose a significant public health burden and current predominant vaccines, while the most effective means of combatting the disease, provide sub-optimal protection. New more broadly effective vaccines are an important public health need.
Influenza hemagglutinin (HA) is the principal viral surface protein that induces protective immunity to influenza infection. A recombinant seasonal influenza hemagglutinin (rHA) vaccine, recently introduced in the U.S., has demonstrated promising efficacy and safety in a number of clinical trials in adults. The immunodominant globular head of the HA protein induces antibodies that are narrowly specific to individual antigenically varied strains of influenza virus, resulting in poor affinity for antigenically drifted strains and the need for repeated annual vaccination. Broader spectrum protection may be achieved with immunity directed at more conserved viral antigens. We reviewed the data from clinical trials of the rHA vaccine conducted during seasonal epidemics characterized by antigenic mismatch between vaccine and circulating strains of influenza. Expert commentary: These data suggest that the rHA proteins produced in Lepidopteran cells offer broader-spectrum protection and result in clinical benefit.
流感在全球每年都会引发疫情，给公共卫生带来重大负担。当前的主流疫苗虽是对抗该疾病的最有效手段，但提供的保护并不理想。研发更具广泛效力的新型疫苗是一项重要的公共卫生需求。
流感血凝素（HA）是诱导针对流感感染产生保护性免疫的主要病毒表面蛋白。美国最近推出的一种重组季节性流感血凝素（rHA）疫苗，在多项成人临床试验中已显示出有前景的疗效和安全性。HA蛋白的免疫显性球状头部诱导产生的抗体对个别抗原性不同的流感病毒株具有狭窄的特异性，导致对抗原性漂移株的亲和力较差，因此需要每年重复接种疫苗。针对更保守的病毒抗原的免疫可能实现更广泛的保护。我们回顾了在季节性疫情期间进行的rHA疫苗临床试验数据，这些疫情的特点是疫苗与流行的流感毒株之间存在抗原不匹配。专家评论：这些数据表明，在鳞翅目细胞中产生的rHA蛋白提供了更广泛的保护并带来了临床益处。
